<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00529204</url>
  </required_header>
  <id_info>
    <org_study_id>200715325</org_study_id>
    <secondary_id>H80-MC-X006</secondary_id>
    <nct_id>NCT00529204</nct_id>
  </id_info>
  <brief_title>Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease</brief_title>
  <official_title>Effects Of Exenatide (Byetta®) On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Non-Alcoholic Fatty Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amylin Pharmaceuticals, LLC.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are common
      complications of type 2 diabetes and leading causes of liver disease in the US and Europe.
      The prevalence of NAFLD and NASH are expected to become a major cause of liver disease
      related deaths and liver transplantation. Currently, there are no specific therapies that
      alter the natural history of NAFLD.Preliminary evidence suggests that exenatide (Byetta®) may
      have several beneficial direct and indirect effects on NAFLD and liver lipid metabolism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preliminary evidence suggests that exenatide (Byetta®) may have several beneficial direct and
      indirect effects on NAFLD and liver lipid metabolism. Ad hoc analysis of phase III studies
      has shown that exenatide treatment is associated with improvement and normalization of
      alanine aminotransferase (ALT), a marker of liver injury, and that this effect is most
      pronounced in those with the greatest weight loss. In addition, treatment of leptin deficient
      ob/ob mice with exenatide reduced weight, liver lipid content, serum ALT and liver lipid
      peroxidation. Additional evidence suggests that the effects of exenatide on the liver are not
      simply a result of weight loss, but rather due to direct effects on the liver. Hepatocytes
      express GLP-1 receptors that are responsive to both GLP-1 and exenatide. Furthermore,
      exenatide treatment of ob/ob mice or isolated hepatocytes reduces mRNA for stearoyl-CoA
      desaturase-1 (SCD-1) and SREBP-1c, which would be expected to reduce DNL.

      Based upon this data, we hypothesize that exenatide treatment of diabetic patients with NAFLD
      and NASH will reduce liver injury through multiple mechanisms including weight reduction
      associated with exenatide, improved lipid metabolism by decreased expression of hepatic genes
      involved in DNL and reduction of adipokines and cytokines associated with severe NASH. This
      study is aimed to address the potential safety and efficacy of exenatide in the treatment of
      NAFLD and test these hypotheses.

      This will be an open label, single-arm, non-comparative trial of 20 patients with type 2
      diabetes and NAFLD treated with exenatide for 6 months with the following specific aims to be
      assessed:

      Determine the safety and efficacy of 24 weeks of exenatide treatment in diabetic patients
      with Non-Alcoholic Fatty Liver Disease (NAFLD) Efficacy will be measured by changes in serum
      ALT (primary endpoint) and liver histology.

      Characterize the effects of exenatide on serum levels of adipokines and inflammatory
      cytokines including adiponectin, leptin and TNF- in NAFLD patients.

      Compare the hepatic expression of SCD1, SREBP-1c and PPAR- mRNA in NAFLD patients pre- and
      post-treatment with exenatide.

      Establish the effects of exenatide on post-prandial lipid metabolism.

      Determine the effects of exenatide on liver fibrosis in NAFLD.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of recruitment
  </why_stopped>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Serum ALT From Baseline to 24 Weeks of Exenatide Therapy</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Components of Liver Histology at Baseline and Week 24 Including Steatosis, Inflammation and Fibrosis</measure>
    <time_frame>24 weeks</time_frame>
    <description>Steatosis was grades on a scale of 0 (&lt; 5%); 1 (5%- 33%); 2 (&gt; 33% - 66%); and 3 (&gt; 66%).
Inflammation was graded on a scale of 0 (No foci); 1 (&lt; 2 foci per 200 X field); 2 (2-4 foci per 200 X field); and 3 (&gt;4 foci per 200 X field) Fibrosis was graded on a scale of 0 (None); 1 (Mild periportal or perisinusoidal); 2 (Moderate periportal or perisinusoidal); 3 (Bridging fibrosis); and 4 (cirrhosis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Exenatide in Patients With NAFLD and Type 2 Diabetes</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Diabetes Complications</condition>
  <condition>Fatty Liver</condition>
  <arm_group>
    <arm_group_label>Exenatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>exenatide 5 µg BID s.c. daily for 28 days, followed by 10 µg BID s.c. daily from day 29 to week 24</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>exenatide</intervention_name>
    <description>Subjects meeting the inclusion criteria will be treated with exenatide 5 µg BID s.c. for 3-7 days, followed by 10 µg BID s.c. daily to week 24</description>
    <arm_group_label>Exenatide</arm_group_label>
    <other_name>BYETTA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years, &lt; 70 years, inclusive

          -  Type 2 diabetes on stable doses of sulfonylurea and/or metformin

          -  Body mass index &gt; 35 kg/m2

          -  Presumed diagnosis of NAFLD based upon

          -  an ALT &gt; 1.5 times the upper limit of reference range,

          -  no evidence of other causes of liver disease and

          -  ultrasound findings compatible with fatty liver

        Exclusion Criteria:

          -  Clinical signs of cirrhosis as evidenced by any of the following

          -  spider angiomata,

          -  splenomegaly,

          -  ascites

          -  jaundice

          -  encephalopathy

          -  INR &gt; 1.2

          -  Platelet count &lt; 100,000/ml

          -  Serum albumin &lt; 3.0 g/dL

          -  Other liver disease including chronic viral hepatitis (B or C), alcohol abuse,
             hemochromatosis, alpha-1 antitrypsin deficiency, autoimmune hepatitis, Wilson's
             disease, primary sclerosing cholangitis or primary biliary cirrhosis.

          -  Current use of &gt; 20 g of alcohol per day or unwillingness to avoid alcohol during the
             course of the study

          -  Treatment with a thiazolidinedione or exenatide within 6 months of enrolling in the
             study

          -  AST or ALT &gt; 10 times the upper limit of normal

          -  Treatment with any investigational drug within 4 weeks of enrollment

          -  Pre-menopausal, fertile women unwilling to use contraceptives during the study period.

          -  Pregnancy or lactation

          -  Initiation or change in dose of hypolipidemic drugs (statins, niacin, cholestyramine
             are allowed) within 6 months of enrollment

          -  Use of anticoagulation, bleeding disorders or other contraindications to liver biopsy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher L Bowlus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lars Berglund, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.liverfoundation.org</url>
    <description>American Liver Foundation</description>
  </link>
  <reference>
    <citation>Buse JB, Klonoff DC, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Maggs DG, Wintle ME. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther. 2007 Jan;29(1):139-53.</citation>
    <PMID>17379054</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2007</study_first_submitted>
  <study_first_submitted_qc>September 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2007</study_first_posted>
  <results_first_submitted>December 8, 2014</results_first_submitted>
  <results_first_submitted_qc>December 15, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 22, 2014</results_first_posted>
  <last_update_submitted>May 25, 2017</last_update_submitted>
  <last_update_submitted_qc>May 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fatty Liver</keyword>
  <keyword>Nonalcoholic fatty liver disease</keyword>
  <keyword>NAFDL</keyword>
  <keyword>Diabetes</keyword>
  <keyword>ALT</keyword>
  <keyword>exenatide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Diabetes Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Exenatide</title>
          <description>exenatide 5 µg BID s.c. daily for 28 days, followed by 10 µg BID s.c. daily from day 29 to week 24
exenatide: Subjects meeting the inclusion criteria will be treated with exenatide 5 µg BID s.c. for 3-7 days, followed by 10 µg BID s.c. daily to week 24</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Exenatide</title>
          <description>exenatide 5 µg BID s.c. daily for 28 days, followed by 10 µg BID s.c. daily from day 29 to week 24
exenatide: Subjects meeting the inclusion criteria will be treated with exenatide 5 µg BID s.c. for 3-7 days, followed by 10 µg BID s.c. daily to week 24</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alanine aminotransferase</title>
          <units>IU</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glucose</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cholesterol</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HDL</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglyceride</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="482"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>hsCRP</title>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Reduction in Serum ALT From Baseline to 24 Weeks of Exenatide Therapy</title>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>exenatide 5 µg BID s.c. daily for 28 days, followed by 10 µg BID s.c. daily from day 29 to week 24
exenatide: Subjects meeting the inclusion criteria will be treated with exenatide 5 µg BID s.c. for 3-7 days, followed by 10 µg BID s.c. daily to week 24</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction in Serum ALT From Baseline to 24 Weeks of Exenatide Therapy</title>
          <units>IU</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Components of Liver Histology at Baseline and Week 24 Including Steatosis, Inflammation and Fibrosis</title>
        <description>Steatosis was grades on a scale of 0 (&lt; 5%); 1 (5%- 33%); 2 (&gt; 33% - 66%); and 3 (&gt; 66%).
Inflammation was graded on a scale of 0 (No foci); 1 (&lt; 2 foci per 200 X field); 2 (2-4 foci per 200 X field); and 3 (&gt;4 foci per 200 X field) Fibrosis was graded on a scale of 0 (None); 1 (Mild periportal or perisinusoidal); 2 (Moderate periportal or perisinusoidal); 3 (Bridging fibrosis); and 4 (cirrhosis)</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>exenatide 5 µg BID s.c. daily for 28 days, followed by 10 µg BID s.c. daily from day 29 to week 24
exenatide: Subjects meeting the inclusion criteria will be treated with exenatide 5 µg BID s.c. for 3-7 days, followed by 10 µg BID s.c. daily to week 24</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Components of Liver Histology at Baseline and Week 24 Including Steatosis, Inflammation and Fibrosis</title>
          <description>Steatosis was grades on a scale of 0 (&lt; 5%); 1 (5%- 33%); 2 (&gt; 33% - 66%); and 3 (&gt; 66%).
Inflammation was graded on a scale of 0 (No foci); 1 (&lt; 2 foci per 200 X field); 2 (2-4 foci per 200 X field); and 3 (&gt;4 foci per 200 X field) Fibrosis was graded on a scale of 0 (None); 1 (Mild periportal or perisinusoidal); 2 (Moderate periportal or perisinusoidal); 3 (Bridging fibrosis); and 4 (cirrhosis)</description>
          <units>units on a scale</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>steatosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>inflammation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>fibrosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety of Exenatide in Patients With NAFLD and Type 2 Diabetes</title>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>exenatide 5 µg BID s.c. daily for 28 days, followed by 10 µg BID s.c. daily from day 29 to week 24
exenatide: Subjects meeting the inclusion criteria will be treated with exenatide 5 µg BID s.c. for 3-7 days, followed by 10 µg BID s.c. daily to week 24</description>
          </group>
        </group_list>
        <measure>
          <title>Safety of Exenatide in Patients With NAFLD and Type 2 Diabetes</title>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Exenatide</title>
          <description>exenatide 5 µg BID s.c. daily for 28 days, followed by 10 µg BID s.c. daily from day 29 to week 24
exenatide: Subjects meeting the inclusion criteria will be treated with exenatide 5 µg BID s.c. for 3-7 days, followed by 10 µg BID s.c. daily to week 24</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christopher L. Bowlus, MD</name_or_title>
      <organization>University of California Davis Medical Center</organization>
      <phone>916-734-8986</phone>
      <email>chris.bowlus@ucdmc.ucdavis.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

